{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:57:47Z","timestamp":1789181867727,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neuropilin-1(NRP1) is a cofactor that enhances SARS-CoV-2 coronavirus cell infectivity when co-expressed with angiotensin-converting enzyme 2(ACE2). The Renin-Angiotensin System (RAS) is activated in type 2 diabetes (T2D); therefore, the aim of this study was to determine if hypoglycaemia-induced stress in T2D would potentiate serum NRP1(sNRP1) levels, reflecting an increased risk for SARS-CoV-2 infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A case-control study of aged-matched T2D (n = 23) and control (n = 23) subjects who underwent a hyperinsulinemic clamp over 1-hour to hypoglycemia(&amp;lt;40mg\/dl) with subsequent timecourse of 4-hours and 24-hours. Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement determined RAS-related proteins: renin (REN), angiotensinogen (AGT), ACE2, soluble NRP1(sNRP1), NRP1 ligands (Vascular endothelial growth factor, VEGF and Class 3 Semaphorins, SEM3A) and NRP1 proteolytic enzyme (A Disintegrin and Metalloproteinase 9, ADAM9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline RAS overactivity was present with REN elevated and AGT decreased in T2D (p&amp;lt;0.05); ACE2 was unchanged. Baseline sNRP1, VEGF and ADAM9 did not differ between T2D and controls and remained unchanged in response to hypoglycaemia. However, 4-hours post-hypoglycemia, sNRP1, VEGF and ADAM9 were elevated in T2D(p&amp;lt;0.05). SEMA3A was not different at baseline; at hypoglycemia, SEMA3A decreased in controls only. Post-hypoglycemia, SEMA3A levels were higher in T2D versus controls. sNRP1 did not correlate with ACE2, REN or AGT. T2D subjects stratified according to ACE inhibitor (ACEi) therapies showed no difference in sNRP1 levels at either glucose normalization or hypoglycaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hypoglycemia potentiated both plasma sNRP1 level elevation and its ligands VEGF and SEMA3A, likely through an ADAM9-mediated mechanism that was not associated with RAS overactivity or ACEi therapy; however, whether this is protective or promotes increased risk for SARS-CoV-2 infection in T2D is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>, identifier NCT03102801.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.665134","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T07:14:08Z","timestamp":1624432448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?"],"prefix":"10.3389","volume":"12","author":[{"given":"Abu Saleh Md","family":"Moin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Qaissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thozhukat","family":"Sathyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80535-8","article-title":"Neuropilin Is a Semaphorin III Receptor","volume":"90","author":"Kolodkin","year":"1997","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040337597","article-title":"Identification of a Natural Soluble Neuropilin-1 That Binds Vascular Endothelial Growth Factor: In Vivo Expression and Antitumor Activity","volume":"97","author":"Gagnon","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311118","article-title":"Vegf (Vascular Endothelial Growth Factor) Induces NRP1 (Neuropilin-1) Cleavage Via ADAMs (a Disintegrin and Metalloproteinase) 9 and 10 to Generate Novel Carboxy-Terminal Nrp1 Fragments That Regulate Angiogenic Signaling","volume":"38","author":"Mehta","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1115","article-title":"Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection","volume":"43","author":"Moin","year":"2020","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1096\/fj.201800499R","article-title":"Neuropilin-1 Maintains Dimethylarginine Dimethylaminohydrolase 1 Expression in Endothelial Cells, and Contributes to Protection From Angiotensin II-induced Hypertension","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of Blood Glucose Control and Outcomes in Patients With COVID-19 and Pre-Existing Type 2 Diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000185629","article-title":"Discrepancy Between Intrarenal Messenger RNA and Protein Expression of ACE and ACE2 in Human Diabetic Nephropathy","volume":"29","author":"Wang","year":"2009","journal-title":"Am J Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 Activity Is Increased in Patients With Type 1 Diabetes and Vascular Complications","volume":"30","author":"Soro-Paavonen","year":"2012","journal-title":"J Hypertens"},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-019-0870-9","article-title":"Inflammatory Cytokines in Type 2 Diabetes Mellitus as Facilitators of Hypercoagulation and Abnormal Clot Formation","volume":"18","author":"Randeria","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12933-020-01090-9","article-title":"Treating Type 2 Diabetes in COVID-19 Patients: The Potential Benefits of Injective Therapies","volume":"19","author":"Longo","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical Recommendations for the Management of Diabetes in Patients With COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1038\/s41598-020-61531-z","article-title":"Effect of Induced Hypoglycemia on Inflammation and Oxidative Stress in Type 2 Diabetes and Control Subjects","volume":"10","author":"Kahal","year":"2020","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13548","article-title":"Effects of Acute Insulin-Induced Hypoglycaemia on Endothelial Microparticles in Adults With and Without Type 2 Diabetes","volume":"21","author":"Al-Qaissi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e26332","DOI":"10.1371\/journal.pone.0026332","article-title":"From SOMAmer-based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay","volume":"6","author":"Kraemer","year":"2011","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1038\/ncomms15345","article-title":"Connecting Genetic Risk to Disease End Points Through the Human Blood Plasma Proteome","volume":"8","author":"Suhre","year":"2017","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14220","article-title":"Hypoglycaemia in Type 2 Diabetes Exacerbates Amyloid-Related Proteins Associated With Dementia","volume":"23","author":"Moin","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the False Discovery Rate in Behavior Genetics Research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780132309","article-title":"Internal Pilot Studies for Estimating Sample Size","volume":"13","author":"Birkett","year":"1994","journal-title":"Stat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.13.4622","article-title":"In Vivo Administration of Vascular Endothelial Growth Factor (VEGF) and Its Antagonist, Soluble Neuropilin-1, Predicts a Role of VEGF in the Progression of Acute Myeloid Leukemia In Vivo","volume":"100","author":"Schuch","year":"2002","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80534-6","article-title":"Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III","volume":"90","author":"He","year":"1997","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.11.013","article-title":"Targeting VEGF Signalling Via the Neuropilin Co-Receptor","volume":"18","author":"Djordjevic","year":"2013","journal-title":"Drug Discovery Today"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10140","article-title":"VEGF165 Mediates Formation of Complexes Containing VEGFR-2 and Neuropilin-1 That Enhance VEGF165-Receptor Binding","volume":"85","author":"Soker","year":"2002","journal-title":"J Cell Biochem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-008-9097-1","article-title":"Neuropilin Structure Governs VEGF and Semaphorin Binding and Regulates Angiogenesis","volume":"11","author":"Geretti","year":"2008","journal-title":"Angiogenesis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/A:1025884628155","article-title":"Characterization of a New Alternatively Spliced Neuropilin-1 Isoform","volume":"6","author":"Tao","year":"2003","journal-title":"Angiogenesis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygeno.2004.02.001","article-title":"Identification of Two Novel Alternatively Spliced Neuropilin-1 Isoforms","volume":"84","author":"Cackowski","year":"2004","journal-title":"Genomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control","volume":"43","author":"Sardu","year":"2020","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of Blood Glucose Control and Outcomes in Patients With COVID-19 and Pre-Existing Type 2 Diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2011.09.003","article-title":"The Role of ADAM-Mediated Shedding in Vascular Biology","volume":"91","author":"Dreymueller","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.09.089","article-title":"ADAM9 is Present at Endothelial Cell - Cell Junctions and Regulates Monocyte - Endothelial Transmigration","volume":"493","author":"English","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.112.21.3603","article-title":"Metalloprotease-Disintegrins: Modular Proteins Capable of Promoting Cell-Cell Interactions and Triggering Signals by Protein-Ectodomain Shedding","volume":"112","author":"Schlondorff","year":"1999","journal-title":"J Cell Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.09.003","article-title":"Neuron-Derived Semaphorin 3A Is an Early Inducer of Vascular Permeability in Diabetic Retinopathy Via Neuropilin-1","volume":"18","author":"Cerani","year":"2013","journal-title":"Cell Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76492","article-title":"Neuropilin-1 Mediates Myeloid Cell Chemoattraction and Influences Retinal Neuroimmune Crosstalk","volume":"124","author":"Dejda","year":"2014","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19468","article-title":"Association of Plasma Semaphorin 3a With Phenotypes of Diabetic Retinopathy and Nephropathy","volume":"57","author":"Kwon","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri3545","article-title":"Immunological Functions of the Neuropilins and Plexins as Receptors for Semaphorins","volume":"13","author":"Kumanogoh","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.07.003","article-title":"Hypoglycemia at the Time of Covid-19 Pandemic","volume":"14","author":"Shah","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.03.011","article-title":"Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus","volume":"42","author":"Dai","year":"2020","journal-title":"Clin Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0319-7","article-title":"Association Between Hypoglycemia and the Burden of Comorbidities in Hospitalized Vulnerable Older Diabetic Patients: A Cross-Sectional, Population-Based Study","volume":"8","author":"de Decker","year":"2017","journal-title":"Diabetes Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of Hypoglycemia and its Significance in Chronic Kidney Disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.036823","article-title":"In Aptamers They Trust: The Caveats of the SOMAscan Biomarker Discovery Platform From Somalogic","volume":"138","author":"Joshi","year":"2018","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.665134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T07:14:11Z","timestamp":1624432451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.665134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":41,"alternative-id":["10.3389\/fendo.2021.665134"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.665134","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"article-number":"665134"}}